In many types of endocrine cells, coordination between the accelerating and braking actions of GPCR-G protein signaling physiologically regulates hormone synthesis and secretion 4,7,8,9,10,11
Research shows that gastrointestinal side effects from GLP-1 medications occur in 50-60% of users during dose initiation, but they're typically mild to moderate and resolve within 2-3 weeks as your body adjusts
This personalized data is worth more than any generic timing recommendation
1996;271:E64348
As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdams criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97)
Many thought leaders recommend either decreasing or eliminating the sulfonylurea at the initiation of a GLP-1 agonist